Clinical Trial Update: Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response [Phase 4]

View source ↗

Summary

Phase 4 trial updating nivolumab dose optimization in melanoma patients who have complete, partial, or stable response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Melanoma | Phase 4 | Status: RECRUITING